title: Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective.
authors.affiliation: Department of Medicine, University of California, San Francisco, CA, USA.
authors.forename: Jennifer C
authors.initials: JC
authors.lastname: Price
authors.forename: Norah A
authors.initials: NA
authors.lastname: Terrault
mesh_terms: D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D012008:Recurrence; D012254:Ribavirin / Q000627:therapeutic use*; D000069474:Sofosbuvir; D016896:Treatment Outcome; D014542:Uridine Monophosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014850:Waiting Lists
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D014542:Uridine Monophosphate; D000069474:Sofosbuvir